Do analysts prefer BBIO or TAK?

BridgeBio Pharma presently has a consensus target price of $89.59, suggesting a potential upside of 40.55%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BridgeBio Pharma 1 Sell rating(s) 2 Hold rating(s) 23 Buy rating(s) 0 Strong Buy rating(s) 2.85 Takeda Pharmaceutical 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50

Does the media favor BBIO or TAK?

In the previous week, BridgeBio Pharma had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for BridgeBio Pharma and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.09 beat BridgeBio Pharma's score of 0.64 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Takeda Pharmaceutical 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, ARGX or BBIO?

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio argenex $4.25B 11.68 $1.29B $22.46 35.53 BridgeBio Pharma $502.08M 24.87 -$724.93M -$3.74 N/A

Does the media favor ARGX or BBIO?

In the previous week, BridgeBio Pharma had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for BridgeBio Pharma and 7 mentions for argenex. BridgeBio Pharma's average media sentiment score of 0.64 beat argenex's score of 0.58 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment argenex 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ONC or BBIO?

In the previous week, BridgeBio Pharma had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 14 mentions for BridgeBio Pharma and 12 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.64 beat BeOne Medicines' score of 0.02 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RVMD or BBIO?

In the previous week, Revolution Medicines had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for Revolution Medicines and 14 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.64 beat Revolution Medicines' score of 0.60 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Revolution Medicines 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive BridgeBio Pharma 4 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

BridgeBio Pharma (BBIO) Competitors

$62.89 -0.99 (-1.55%)

As of 09:30 AM Eastern

Compare

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

Should you buy BridgeBio Pharma stock or one of its competitors? MarketBeat compares BridgeBio Pharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with BridgeBio Pharma include Takeda Pharmaceutical (TAK), argenex (ARGX), Teva Pharmaceutical Industries (TEVA), BeOne Medicines (ONC), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

BridgeBio Pharma (NASDAQ:BBIO) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

In the previous week, BridgeBio Pharma had 12 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 14 mentions for BridgeBio Pharma and 2 mentions for Takeda Pharmaceutical. Takeda Pharmaceutical's average media sentiment score of 1.09 beat BridgeBio Pharma's score of 0.64 indicating that Takeda Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma presently has a consensus target price of $89.59, suggesting a potential upside of 40.55%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
Takeda Pharmaceutical	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.50

99.9% of BridgeBio Pharma shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 14.2% of BridgeBio Pharma shares are owned by company insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BridgeBio Pharma has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Takeda Pharmaceutical has a beta of -0.07, suggesting that its stock price is 107% less volatile than the broader market.

Takeda Pharmaceutical has a net margin of 4.31% compared to BridgeBio Pharma's net margin of -124.42%. Takeda Pharmaceutical's return on equity of 11.07% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Takeda Pharmaceutical	4.31%	11.07%	5.49%

Takeda Pharmaceutical has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	24.87	-$724.93M	-$3.74	N/A
Takeda Pharmaceutical	$28.32B	1.67	$1.27B	$0.39	38.18

Summary

BridgeBio Pharma and Takeda Pharmaceutical tied by winning 8 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to argenex?

argenex (NASDAQ:ARGX) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and profitability.

argenex has a net margin of 31.31% compared to BridgeBio Pharma's net margin of -124.42%. argenex's return on equity of 33.28% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
argenex	31.31%	33.28%	28.16%
BridgeBio Pharma	-124.42%	N/A	-65.81%

argenex has a beta of 0.47, indicating that its share price is 53% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market.

60.3% of argenex shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 2.4% of argenex shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

argenex has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
argenex	$4.25B	11.68	$1.29B	$22.46	35.53
BridgeBio Pharma	$502.08M	24.87	-$724.93M	-$3.74	N/A

argenex currently has a consensus target price of $1,019.50, indicating a potential upside of 27.75%. BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 40.55%. Given BridgeBio Pharma's higher probable upside, analysts plainly believe BridgeBio Pharma is more favorable than argenex.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
argenex	0 Sell rating(s)	4 Hold rating(s)	18 Buy rating(s)	2 Strong Buy rating(s)	2.92
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

In the previous week, BridgeBio Pharma had 7 more articles in the media than argenex. MarketBeat recorded 14 mentions for BridgeBio Pharma and 7 mentions for argenex. BridgeBio Pharma's average media sentiment score of 0.64 beat argenex's score of 0.58 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
argenex	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

argenex beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

BridgeBio Pharma (NASDAQ:BBIO) and Teva Pharmaceutical Industries (NYSE:TEVA) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

99.9% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by insiders. Comparatively, 0.5% of Teva Pharmaceutical Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Teva Pharmaceutical Industries has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Teva Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BridgeBio Pharma	$502.08M	24.87	-$724.93M	-$3.74	N/A
Teva Pharmaceutical Industries	$17.26B	2.19	$1.41B	$1.33	24.75

BridgeBio Pharma currently has a consensus target price of $89.59, indicating a potential upside of 40.55%. Teva Pharmaceutical Industries has a consensus target price of $41.78, indicating a potential upside of 26.90%. Given BridgeBio Pharma's stronger consensus rating and higher possible upside, research analysts plainly believe BridgeBio Pharma is more favorable than Teva Pharmaceutical Industries.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85
Teva Pharmaceutical Industries	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Teva Pharmaceutical Industries has a net margin of 9.01% compared to BridgeBio Pharma's net margin of -124.42%. Teva Pharmaceutical Industries' return on equity of 43.53% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BridgeBio Pharma	-124.42%	N/A	-65.81%
Teva Pharmaceutical Industries	9.01%	43.53%	8.19%

In the previous week, Teva Pharmaceutical Industries had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for Teva Pharmaceutical Industries and 14 mentions for BridgeBio Pharma. Teva Pharmaceutical Industries' average media sentiment score of 1.37 beat BridgeBio Pharma's score of 0.64 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Teva Pharmaceutical Industries	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BridgeBio Pharma has a beta of 0.97, meaning that its stock price is 3% less volatile than the broader market. Comparatively, Teva Pharmaceutical Industries has a beta of 0.84, meaning that its stock price is 16% less volatile than the broader market.

Summary

Teva Pharmaceutical Industries beats BridgeBio Pharma on 9 of the 16 factors compared between the two stocks.

How does BridgeBio Pharma compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

In the previous week, BridgeBio Pharma had 2 more articles in the media than BeOne Medicines. MarketBeat recorded 14 mentions for BridgeBio Pharma and 12 mentions for BeOne Medicines. BridgeBio Pharma's average media sentiment score of 0.64 beat BeOne Medicines' score of 0.02 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has higher revenue and earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	5.60	$286.93M	$4.47	61.05
BridgeBio Pharma	$502.08M	24.87	-$724.93M	-$3.74	N/A

BeOne Medicines has a net margin of 8.94% compared to BridgeBio Pharma's net margin of -124.42%. BeOne Medicines' return on equity of 12.06% beat BridgeBio Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
BridgeBio Pharma	-124.42%	N/A	-65.81%

BeOne Medicines presently has a consensus target price of $390.00, indicating a potential upside of 42.91%. BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 40.55%. Given BeOne Medicines' higher possible upside, research analysts clearly believe BeOne Medicines is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.80
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

48.6% of BeOne Medicines shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 6.2% of BeOne Medicines shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

BeOne Medicines beats BridgeBio Pharma on 9 of the 17 factors compared between the two stocks.

How does BridgeBio Pharma compare to Revolution Medicines?

Revolution Medicines (NASDAQ:RVMD) and BridgeBio Pharma (NASDAQ:BBIO) are both large-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, dividends, institutional ownership, media sentiment, analyst recommendations and earnings.

Revolution Medicines presently has a consensus target price of $123.72, indicating a potential downside of 19.01%. BridgeBio Pharma has a consensus target price of $89.59, indicating a potential upside of 40.55%. Given BridgeBio Pharma's higher possible upside, analysts clearly believe BridgeBio Pharma is more favorable than Revolution Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Revolution Medicines	1 Sell rating(s)	1 Hold rating(s)	17 Buy rating(s)	3 Strong Buy rating(s)	3.00
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Revolution Medicines has a beta of 1.4, indicating that its stock price is 40% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

94.3% of Revolution Medicines shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 7.6% of Revolution Medicines shares are held by company insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Revolution Medicines had 3 more articles in the media than BridgeBio Pharma. MarketBeat recorded 17 mentions for Revolution Medicines and 14 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.64 beat Revolution Medicines' score of 0.60 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Revolution Medicines	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
BridgeBio Pharma	4 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Revolution Medicines has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. BridgeBio Pharma's return on equity of 0.00% beat Revolution Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Revolution Medicines	N/A	-83.22%	-59.06%
BridgeBio Pharma	-124.42%	N/A	-65.81%

BridgeBio Pharma has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than BridgeBio Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Revolution Medicines	$11.58M	2,804.45	-$1.13B	-$7.07	N/A
BridgeBio Pharma	$502.08M	24.87	-$724.93M	-$3.74	N/A

Summary

BridgeBio Pharma beats Revolution Medicines on 10 of the 17 factors compared between the two stocks.

Get BridgeBio Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BBIO vs. The Competition

Export

Metric	BridgeBio Pharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.48B	$5.89B	$6.32B	$12.58B
Dividend Yield	N/A	0.68%	2.69%	5.45%
P/E Ratio	-17.04	8.34	21.04	24.56
Price / Sales	24.87	21.27	561.99	126.87
Price / Cash	N/A	8.35	42.31	57.88
Price / Book	-5.92	4.08	9.83	6.75
Net Income	-$724.93M	$102.24M	$3.56B	$337.19M
7 Day Performance	-4.06%	-1.46%	-0.44%	1.88%
1 Month Performance	-7.03%	2.49%	4.58%	6.59%
1 Year Performance	69.89%	126.80%	27.58%	35.52%

BridgeBio Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BBIO BridgeBio Pharma	3.4939 of 5 stars	$63.74 -0.2%	$89.59 +40.6%	+80.1%	$12.48B	$502.08M	N/A	400	Analyst Forecast
TAK Takeda Pharmaceutical	3.6929 of 5 stars	$16.22 -0.2%	N/A	+0.8%	$51.71B	$28.32B	41.60	47,455
ARGX argenex	4.2117 of 5 stars	$806.46 flat	$1,017.78 +26.2%	+37.2%	$49.91B	$4.25B	35.91	1,863	Analyst Forecast
TEVA Teva Pharmaceutical Industries	4.8968 of 5 stars	$34.04 -0.1%	$41.78 +22.7%	+91.1%	$39.17B	$17.26B	25.59	33,950	Positive News
ONC BeOne Medicines	4.4002 of 5 stars	$310.25 flat	$389.15 +25.4%	+11.7%	$34.04B	$5.34B	69.41	12,000	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BBIO) was last updated on 6/3/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Summary

How does BridgeBio Pharma compare to argenex?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

BridgeBio Pharma (BBIO) Competitors

BBIO vs. TAK, ARGX, TEVA, ONC, and RVMD

How does BridgeBio Pharma compare to Takeda Pharmaceutical?

Does the media favor BBIO or TAK?

Do analysts prefer BBIO or TAK?

Do institutionals & insiders hold more shares of BBIO or TAK?

Which has more volatility & risk, BBIO or TAK?

Is BBIO or TAK more profitable?

Which has preferable valuation and earnings, BBIO or TAK?

Summary

How does BridgeBio Pharma compare to argenex?

Is ARGX or BBIO more profitable?

Which has more volatility and risk, ARGX or BBIO?

Do institutionals & insiders hold more shares of ARGX or BBIO?

Which has preferable earnings and valuation, ARGX or BBIO?

Do analysts rate ARGX or BBIO?

Does the media favor ARGX or BBIO?

Summary

How does BridgeBio Pharma compare to Teva Pharmaceutical Industries?

Do institutionals & insiders hold more shares of BBIO or TEVA?

Which has stronger earnings & valuation, BBIO or TEVA?

Do analysts rate BBIO or TEVA?

Is BBIO or TEVA more profitable?

Does the media refer more to BBIO or TEVA?

Which has more risk & volatility, BBIO or TEVA?

Summary

How does BridgeBio Pharma compare to BeOne Medicines?

Does the media prefer ONC or BBIO?

Which has higher earnings and valuation, ONC or BBIO?

Is ONC or BBIO more profitable?

Do analysts rate ONC or BBIO?

Which has more risk & volatility, ONC or BBIO?

Do insiders and institutionals hold more shares of ONC or BBIO?

Summary

How does BridgeBio Pharma compare to Revolution Medicines?

Do analysts prefer RVMD or BBIO?

Which has more risk & volatility, RVMD or BBIO?

Do insiders and institutionals believe in RVMD or BBIO?

Does the media prefer RVMD or BBIO?

Is RVMD or BBIO more profitable?

Which has preferable valuation and earnings, RVMD or BBIO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BBIO vs. The Competition

BridgeBio Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools